– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17 using 100 million cells in the second dose cohort–
– DSG3-CAART persistence observed in
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.45) per share. This is a 28.57 percent decrease over losses of $(0.35) per share from the same period last year.